ロード中...
Estimation of absorbed dose to the kidneys in patients after treatment with (177)Lu-octreotate: comparison between methods based on planar scintigraphy
BACKGROUND: Lu-[DOTA(0), Tyr(3)]-octreotate ((177)Lu-octreotate) is used to treat neuroendocrine tumors with high somatostatin-receptor expression. (177)Lu-octreotate is mainly excreted via the kidneys, but to some extent, accumulates in the kidney cortex due to, e.g., tubular reabsorption. Renal to...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3506567/ https://ncbi.nlm.nih.gov/pubmed/23006939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-219X-2-49 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|